7+ Year Survival Rates
with LVAD
The HeartMate 3™ Left Ventricular Assist Device (LVAD) provides life-prolonging therapy in a patient population who otherwise would not be expected to survive beyond 9 months.1,2,*
See The Data >
60% survival at 5 years3
Median survival exceeding 7 years1
Want to determine if HeartMate 3 LVAD may prolong your patients lives?
Get the get the latest clinical advancements, education, and patient resources:
Underutilization of HeartMate 3 LVAD in Advanced Heart Failure
In this episode of Between Two Ventricles™ HF Podcast, Michael Zhen-Yu Tong, M.D., MBA, FRCSC, and Dr. Phil Adamson emphasize how median survival with HeartMate 3 LVAD reliably exceeds 5 years, even in those patients with refractory heart failure who are ineligible for transplantation.
Learn more about LVAD therapy with HeartMate 3 LVAD
*Patients on inotropes who did not receive a transplant or left ventricular assist device.
References
- Nayak A, Cascino TM, DeFilippis EM, et al. The Society of Thoracic Surgeons Intermacs 2025 Annual Report: Focus on outcomes in older adults. Ann Thorac Surg. 2025 Oct 31. doi:10.1016/j.athoracsur.2025.10.005
- Sami F, Acharya P, Noonan G, et al. Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine. J Card Fail. 2022;28(12):1683-1691. doi:10.1016/j.cardfail.2022.08.007
- Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Tria. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197
MAT-2412503 v2.0